← Back to patent-cliff list
Neumifil(Pneumagen)
Tier C — Watch / tradeNeumifil(Pneumagen)
Pneumagen Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Indications (approved)：Influenza virus infection, Respiratory viral infection, Respiratory tract infection, 呼吸道合胞体病毒感染, COVID-19
Regional status
US
-
EU
Phase II
2022-08-12
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Neumifil(Pneumagen)?
Approved indications include: Influenza virus infection, Respiratory viral infection, Respiratory tract infection, 呼吸道合胞体病毒感染, COVID-19.
When does the Neumifil(Pneumagen) patent expire?
No public expiry year is available for Neumifil(Pneumagen) yet; this page updates once verified.
How do I get a quote for Neumifil(Pneumagen) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05